GABA Signaling Accelerates Glioblastoma in Female Mice via gMDSCs, Extending Survival With GABBR Blockade
Updated
Updated · Nature.com · Jun 23
GABA Signaling Accelerates Glioblastoma in Female Mice via gMDSCs, Extending Survival With GABBR Blockade
3 articles · Updated · Nature.com · Jun 23
Summary
Female mouse glioblastoma models worsened when GABBR was activated: baclofen sped tumor progression and shortened survival, while a GABBR antagonist prolonged survival only in immunocompetent females.
100 μM GABA or baclofen boosted the T cell-suppressive activity of female granulocytic myeloid-derived suppressor cells by increasing CAT2-linked arginine metabolism, NOS2 expression and peroxynitrite production.
That immune effect appeared sex-specific and microenvironment-driven: male mice and immunocompromised mice saw no survival impact, and GABA or baclofen did not directly increase glioblastoma cell proliferation in vitro.
Human data pointed the same way—immune cells from women with glioblastoma showed stronger GABA-related transcriptional signatures, higher GABBR expression in neutrophil/gMDSC-like cells, and higher tumor GABA levels than men.
The study suggests GABBR inhibition could become a sex-specific immunotherapy strategy for glioblastoma, a cancer with median survival of about 18–20 months.
If GABA drives cancer in women, what other diseases have hidden sex-specific neurotransmitter triggers?
Can blocking a common brain chemical become the first targeted therapy for women with glioblastoma?
Sex-Specific Mechanisms Drive Glioblastoma Progression: GABA-GABBR Axis Identified as Key Therapeutic Target for Female GBM Patients
Overview
A major new study has revealed that Glioblastoma (GBM) progresses differently in males and females. In males, the disease is mainly driven by monocytic myeloid-derived suppressor cells (mMDSCs), while in females, granulocytic myeloid-derived suppressor cells (gMDSCs) play the key role. This discovery highlights the importance of sex-specific pathways in GBM and suggests that targeting gMDSCs or related immune pathways could lead to more effective treatments for women. These findings challenge the traditional one-size-fits-all approach and open the door to personalized therapies based on a patient’s sex.